Bay Area's Tricia Closes $57.5M Series D, Pushes Into Phase III Trial Post author:Sam Post published:November 7, 2017 Post category:BioPharma Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101. Source: BioSpace You Might Also Like Bay Area's Carmot Lands $240M+ R&D Tie-Up With Biotech Giant Amgen December 5, 2017 Rumors Swirl of a Smith & Nephew Takeover with Stryker and Medtronic as Top Buyers October 19, 2017 Belgium Biotech Ablynx Files For $150 Million U.S. IPO Right After Phase III Boost October 2, 2017